# US 2019/0316132 A1 · Thermostable polymerase inhibitor compositions and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0316132 A1
- Document ID: US20190316132A1
- Status: Published application
- Kind: A1
- Application number: 16/305,858
- Filed: 2017-06-06
- Published: 2019-10-17
- Earliest claimed: 2016-06-07
- Assignees: Cepheid
- Applicants: Cepheid
- Inventors: Sergey G. Lokhov; Alexander A. Gall; Vera Baraznenok; Ekaterina V. Viazovkina; Irina Shishkina; David H. Persing
- Web page: https://patentgrep.com/patent/US20190316132A1

## CPC

- C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- C12Q 1/6844: Nucleic acid amplification reactions
- C12Q 1/6853: using modified primers or templates
- C12Q 1/686: Polymerase chain reaction [PCR]
- C12N 2310/16: Aptamers
- C12N 2310/531: Stem-loop; Hairpin
- C12N 2310/532: Closed or circular
- C12N 2320/52: modulating the physical stability, e.g. GC-content
- C12Q 2525/205: Aptamer
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present disclosure relates to aptamers for temperature-dependent reversible inhibition of thermostable polymerase activity in order to improve sensitivity and specificity of various reactions and assays involving hot start polynucleotide synthesis. Methods for use of the aptamers and related compositions and kits are also provided.

## Claims

### Claim 1

An aptamer comprising in a 5′ to 3′ direction:
a first sequence comprising SEQ ID NO:1 or a variant thereof or SEQ ID NO:2 or a variant thereof,
a second sequence comprising SEQ ID NO:3 or a variant thereof,
a third sequence comprising SEQ ID NO:1 or a variant thereof or SEQ ID NO:2 or a variant thereof,
and a fourth sequence comprising SEQ ID NO:3 or a variant thereof,
wherein each of the first and third sequences are 14-18 nucleotides in length, are equal in length to each other, and are 100% complementary to each other along their entire length; and
wherein the second and fourth sequences are 12 nucleotides in length and are identical to each other.

### Claim 2 (depends on 1)

The aptamer of claim 1, wherein there is a covalent bond between the 5′ end of the first sequence and the 3′ end of the fourth sequence.

### Claim 3 (depends on 2)

The aptamer of claim 2, wherein the covalent bond is a phosphodiester bond.

### Claim 4 (depends on 2, 3)

The aptamer of claim 2 or 3, wherein there is no covalent bond between 2 of the nucleotides within the first sequence and wherein the aptamer comprises a 5′ terminus and a 3′ terminus.

### Claim 5 (depends on 2, 3)

The aptamer of claim 2 or 3, wherein there is no covalent bond between 2 of the nucleotides within the third sequence and wherein the aptamer comprises a 5′ terminus and a 3′ terminus.

### Claim 6 (depends on 2, 3, 4, 5)

The aptamer of claim any one of claims 2 to 5, wherein the first sequence comprises SEQ ID NO:1, the third sequence comprises SEQ ID NO:2, and there is no covalent bond between nucleotides 8 and 9 of SEQ ID NO:1.

### Claim 7 (depends on 2, 3, 4, 5)

The aptamer of claim any one of claims 2 to 5, wherein the first sequence comprises SEQ ID NO:2, the third sequence comprises SEQ ID NO:2, and there is no covalent bond between nucleotides 8 and 9 of SEQ ID NO:2.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

The aptamer of any one of claims 1 to 6, wherein the first sequence comprises SEQ ID NO:2 and the third sequence comprises SEQ ID NO:3.

### Claim 9

The aptamer of any one of the preceding claims, wherein the first and third sequences are hybridized to each other along the entire length of each of the first and third sequences.

### Claim 10 (depends on 9)

The aptamer of claim 9, wherein there are no mismatches between the first and third sequences.

### Claim 11 (depends on 6)

The aptamer of claim 6, wherein the aptamer comprises SEQ ID NO:106

### Claim 12 (depends on 7)

The aptamer of claim 7, wherein the aptamer comprises SEQ ID NO:110.

### Claim 13 (depends on 4, 5, 6, 7, 8, 9, 10)

The aptamer of any one of claims 4 to 10, wherein the 5′ terminus is phosphorylated.

### Claim 14 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The aptamer of any one of claims 4 to 13, wherein the 3′ terminus is linked to a 3′ capping moiety.

### Claim 15 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The aptamer of any one of claims 4 to 13, wherein the 5′ terminus is linked to a 5′ capping moiety.

### Claim 16 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The aptamer any one of claims 4 to 13, wherein the 3′ terminus is linked to a 3′ capping moiety and the 5′ terminus is linked to a 5′ capping moiety.

### Claim 17 (depends on 14, 16)

The aptamer of claim 14 or 16, wherein the 3′ capping moiety is a propanediol spacer (C3) or a phosphate.

### Claim 18 (depends on 15, 16)

The aptamer of claim 15 or 16, wherein the 5′ capping moiety is an amino group.

### Claim 19

An aptamer comprising an oligonucleotide comprising in a 5′ to 3′ direction:
a first polynucleotide sequence comprising SEQ ID NO:4 or a variant thereof or SEQ ID NO:5 or a variant thereof,
a second polynucleotide sequence comprising SEQ ID NO:3 or a variant thereof, and
a third polynucleotide sequence comprising SEQ ID NO:5 or a variant thereof or SEQ ID NO:4 or a variant thereof, and
a fourth polynucleotide sequence comprising SEQ ID NO:3 or a variant thereof,
wherein each of the second and fourth sequences are 14-20 nucleotides in length, are equal in length, and are complementary to each other along their entire length; and wherein the aptamer comprises a 5′ end and a 3′ end.

### Claim 20 (depends on 19)

The aptamer of claim 19, wherein the aptamer comprises an oligonucleotide comprising SEQ ID NO:83 or 87.

### Claim 21 (depends on 19)

The aptamer of claim 19, wherein the 3′ end of the fourth sequence is covalently bound to the 5′ end of the first sequence and there is no phosphodiester bond between the last nucleotide of the third sequence and the first nucleotide of the fourth sequence.

### Claim 22 (depends on 21)

The aptamer of claim 21, wherein the aptamer comprises an oligonucleotide comprising SEQ ID NO:84 or 86.

### Claim 23 (depends on 19)

The aptamer of claim 19, wherein the 3′ end of the fourth sequence is covalently bound to the 5′ end of the first sequence and there is no phosphodiester bond between 2 nucleotides within the fourth sequence.

### Claim 24 (depends on 21, 23)

The aptamer of claim 23 or 21, wherein there is no phosphodiester bond between nucleotides 1 and 2, 2 and 3, 3 and 4, 4 and 5, 5 and 6, 6 and 7, 7 and 8, 8 and 9, 9 and 10, 10 and 11 or 11 and 12 of SEQ ID NO:3 in the fourth sequence.

### Claim 25 (depends on 23, 24)

The aptamer of claim 23 or 24, wherein the aptamer comprises an oligonucleotide comprising one of SEQ ID NOs:82, 85 or 88-105.

### Claim 26

An aptamer comprising a sequence selected from the group consisting of SEQ ID NO:82-105.

### Claim 27 (depends on 19, 20, 21, 22, 23, 24, 25, 26)

The aptamer of any one of claims 19 to 26, wherein the 5′ end of the aptamer is linked to a 5′ capping moiety.

### Claim 28 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27)

The aptamer of any one of claims 19 to 27, wherein the 3′ end of the aptamer is linked to a 3′ capping moiety.

### Claim 29 (depends on 27, 28)

The aptamer of claim 27 or 28, wherein the 5′ capping moiety is an amino group.

### Claim 30 (depends on 28, 29)

The aptamer of claim 28 or 29, wherein the 3′ capping moiety is a propanediol spacer (C3) or a phosphate.

### Claim 31

The aptamer of any one of the preceding claims, wherein the aptamer does not inhibit reverse transcriptase activity.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

A composition comprising an aptamer according to any one of claims 1 to 31 and a thermostable polymerase.

### Claim 33 (depends on 32)

The composition of claim 32, wherein the polymerase is selected from the group consisting of Thermus aquaticus, Thermus thermophilus, or Thermus maritima.

### Claim 34 (depends on 32, 33)

The composition of claim 32 or 33, further comprising deoxyribonucleotide triphosphates and a divalent metal cation.

### Claim 35 (depends on 32, 33, 34)

The composition of any one of claims 32 to 34, further comprising a forward primer specific for a target nucleic acid.

### Claim 36 (depends on 32, 33, 34, 35)

The composition of any one of claims 32 to 35, further comprising a reverse primer specific for the target nucleic acid.

### Claim 37 (depends on 32, 33, 34, 35, 36)

The composition of any once of claims 32 to 36, wherein the ratio of the aptamer to the polymerase ranges from about 5:1 to 20:1.

### Claim 38 (depends on 32, 33, 34, 35, 36, 37)

The composition of any one of claims 32 to 37, wherein the composition is a dried composition.

### Claim 39 (depends on 32, 33, 34, 35, 36, 37)

The composition of claim of any one of claims 32 to 37, wherein the composition is a liquid composition.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

A method for extending a primer, comprising:
contacting a sample which might contain a target nucleic acid with a reagent composition to generate a reaction mixture, wherein the reagent composition comprises an aptamer according to any one of claims 1 to 31, a thermostable polymerase, a forward primer specific for the target nucleic acid, deoxyribonucleotide triphosphates, and a divalent metal cation.

### Claim 41 (depends on 40)

The method of claim 40, wherein the reagent composition further comprises a reverse primer specific for the target nucleic acid.

### Claim 42 (depends on 40, 41)

The method of claim 40 or 41, wherein the reagent composition further comprises a reverse transcriptase and wherein the method further comprises performing a reverse transcriptase reaction prior to heating the reaction mixture.

### Claim 43 (depends on 40, 41, 42)

The method of any one of claims claims 40 to 42, wherein the DNA polymerase is selected from the group consisting of Thermus aquaticus, Thermus thermophilus, or Thermus maritima.

### Claim 44 (depends on 40, 41, 42, 43)

The method of any one of claims 40 to 43, wherein the ratio of the aptamer to the polymerase ranges from about 5:1 to 20:1.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

A kit comprising a composition comprising an aptamer according to any one of claims 1 to 31 and a thermostable polymerase.

### Claim 46 (depends on 45)

The kit of claim 45, further comprising deoxyribonucleotide triphosphates and a divalent metal cation.

### Claim 47 (depends on 45, 46)

The kit of claim 45 or 46, wherein the composition is a dried composition.

### Claim 48 (depends on 45, 46, 47)

The kit of any one of claims 45 to 47, further comprising an aqueous buffer.

### Claim 49 (depends on 45, 46, 47, 48)

The kit of any one of claims 45 to 48, wherein the composition further comprises a forward primer specific for a target nucleic acid.

### Claim 50 (depends on 45, 46, 47, 48, 49)

The kit of any one of claims 45 to 49, wherein the composition further comprises a reverse primer specific for the target nucleic acid.

### Claim 51 (depends on 45, 46, 47, 48, 49, 50)

The kit of any one of claims 45 to 50, further comprising a reverse transcriptase.
